Identification of serum cytokine clusters associated with outcomes in ovarian clear cell carcinoma

被引:5
作者
Yabuno, Akira [1 ]
Matsushita, Hirokazu [2 ]
Hamano, Tetsutaro [1 ]
Tan, Tuan Zea [3 ]
Shintani, Daisuke [1 ]
Fujieda, Nao [2 ]
Tan, David S. P. [3 ,4 ,5 ]
Huang, Ruby Yun-Ju [6 ]
Fujiwara, Keiichi [1 ]
Kakimi, Kazuhiro [2 ]
Hasegawa, Kosei [1 ]
机构
[1] Saitama Med Univ, Int Med Ctr, Dept Gynecol Oncol, 1397-1 Yamane, Hidaka, Saitama 3501298, Japan
[2] Univ Tokyo Hosp, Dept Immunotherapeut, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan
[3] Natl Univ Singapore, Canc Sci Inst Singapore, Singapore, Singapore
[4] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Med, Singapore, Singapore
[5] Natl Univ Singapore Hosp, Natl Univ Canc Inst, Singapore, Singapore
[6] Natl Taiwan Univ, Sch Med, Coll Med, Taipei, Taiwan
关键词
DISTINCT-HISTOLOGIC-TYPE; POOR-PROGNOSIS; T-CELLS; CANCER; CHEMOTHERAPY; RESISTANCE; SURVIVAL;
D O I
10.1038/s41598-020-75536-1
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Serum cytokine and chemokine networks may reflect the complex systemic immunological interactions in cancer patients. Studying groups of cytokines and their networks may help to understand their clinical biology. A total of 178 cases of ovarian cancer were analyzed in this study, including 73 high-grade serous (HGSC), 66 clear cell (CCC) and 39 endometrioid carcinomas. Suspension cytokine arrays were performed with the patients' sera taken before the primary surgery. Associations between each cytokine and clinicopathological factors were analyzed in all patients using multivariate linear regression models, and cluster analyses were performed for each histotype. In the multivariate analyses, twelve of 27 cytokines were correlated with histotypes. Cluster analyses in each histotype revealed 2 cytokine signatures S1 and S2 in HGSC, and similarly C1 and C2 in CCC. Twenty-two of 27 cytokines were commonly clustered in HGSC and CCC. Signature S1 and C1 included IL-2,6,8,15, chemokines and angiogenic factors, whereas signature S2 and C2 included IL-4,5,9,10,13, TNF-alpha and G-CSF. Four subgroups based on a high or low level for each signature were identified, and this cluster-based classification demonstrated significantly different progression-free and overall survivals for CCC patients (P=0.00097 and P=0.017).
引用
收藏
页数:10
相关论文
共 50 条
  • [31] Impact of Combination Chemotherapy with Itraconazole on Survival for Patients with Recurrent or Persistent Ovarian Clear Cell Carcinoma
    Tsubamoto, Hiroshi
    Sonoda, Takashi
    Yamasaki, Masaaki
    Inoue, Kayo
    [J]. ANTICANCER RESEARCH, 2014, 34 (04) : 2007 - 2014
  • [32] Serum D-dimer, albumin and systemic inflammatory response markers in ovarian clear cell carcinoma and their prognostic implications
    Chen, Wei
    Zhong, Siyuan
    Shan, Boer
    Zhou, Shuling
    Wu, Xiaohua
    Yang, Huijuan
    Ye, Shuang
    [J]. JOURNAL OF OVARIAN RESEARCH, 2020, 13 (01)
  • [33] Distinct gene expression profiles associated with clinical outcomes in patients with ovarian clear cell carcinoma and high-grade serous ovarian carcinoma
    Zhou, Huimei
    Liu, Qian
    Shi, Xiaohua
    Liu, Yue
    Cao, Dongyan
    Yang, Jiaxin
    [J]. JOURNAL OF OVARIAN RESEARCH, 2020, 13 (01)
  • [34] Loss of ARID1A expression is related to shorter progression-free survival and chemoresistance in ovarian clear cell carcinoma
    Katagiri, Atsuko
    Nakayama, Kentaro
    Rahman, Mohammed Tanjimur
    Rahman, Munmun
    Katagiri, Hiroshi
    Nakayama, Naomi
    Ishikawa, Masako
    Ishibashi, Tomoka
    Iida, Kouji
    Kobayashi, Hiroshi
    Otsuki, Yoshiro
    Nakayama, Satoru
    Miyazaki, Kohji
    [J]. MODERN PATHOLOGY, 2012, 25 (02) : 282 - 288
  • [35] Identification of Potential Serum Proteomic Biomarkers for Clear Cell Renal Cell Carcinoma
    Yang, Juan
    Yang, Jin
    Gao, Yan
    Zhao, Lingyu
    Liu, Liying
    Qin, Yannan
    Wang, Xiaofei
    Song, Tusheng
    Huang, Chen
    [J]. PLOS ONE, 2014, 9 (11):
  • [36] Antioxidants and Therapeutic Targets in Ovarian Clear Cell Carcinoma
    Amano, Tsukuru
    Murakami, Atsushi
    Murakami, Takashi
    Chano, Tokuhiro
    [J]. ANTIOXIDANTS, 2021, 10 (02) : 1 - 15
  • [37] Molecular changes in endometriosis-associated ovarian clear cell carcinoma
    Worley, Michael J., Jr.
    Liu, Shubai
    Hua, Yuanyuan
    Kwok, Jamie Sui-Lam
    Samuel, Anicka
    Hou, Lei
    Shoni, Melina
    Lu, Shi
    Sandberg, Evelien M.
    Keryan, Anna
    Wu, Di
    Ng, Shu-Kay
    Kuo, Winston P.
    Parra-Herran, Carlos E.
    Tsui, Stephen K. W.
    Welch, William
    Crum, Christopher
    Berkowitz, Ross S.
    Ng, Shu-Wing
    [J]. EUROPEAN JOURNAL OF CANCER, 2015, 51 (13) : 1831 - 1842
  • [38] IKBKB expression in clear cell renal cell carcinoma is associated with tumor grade and patient outcomes
    Krazinski, Bartlomiej E.
    Kowalczyk, Anna E.
    Sliwinska-Jewsiewicka, Agnieszka
    Grzegrzolka, Jedrzej
    Godlewski, Janusz
    Kwiatkowski, Przemyslaw
    Dziegiel, Piotr
    Kmiec, Zbigniew
    Kiewisz, Jolanta
    [J]. ONCOLOGY REPORTS, 2019, 41 (02) : 1189 - 1197
  • [39] Preoperative serum microRNAs as potential prognostic biomarkers in ovarian clear cell carcinoma
    Suzuki, Kazuhiro
    Yokoi, Akira
    Yoshida, Kosuke
    Kato, Tomoyasu
    Ochiya, Takahiro
    Yamamoto, Yusuke
    Kajiyama, Hiroaki
    [J]. JOURNAL OF GYNECOLOGIC ONCOLOGY, 2023, 34 (03)
  • [40] Common and specific genes in ovarian clear cell carcinoma and serous carcinoma by gene expression analysis
    Cao, Wenjiao
    Wang, Lihua
    [J]. TRANSLATIONAL CANCER RESEARCH, 2018, 7 (06) : 1501 - 1509